Active

COLE PHARMACEUTICALS

Switched

BE0671904152

Rechtspersoon Private limited company 1 establishment

Rue André Dumont 7, 1435 Mont-Saint-Guibert Groothandel in farmaceutische en medische artikelen

Active for

9 year, 6 months

Financials

Financial year 2025

Worth noting

  • A loss two years in a row.
  • Little cash and receivables against the short-term debts.
  • Figures corrected afterwards (2022).

Gross margin

€ -168,161

▲ 60% vs 2024

Profit

Caution

€ -390,094

▲ 34% vs 2024

Debts

Normal

€ 1 million

▼ 39% vs 2024

COLE PHARMACEUTICALS from Mont-Saint-Guibert, company number BE0671904152, closed financial year 2025 with a result of € -390,094 after tax. For that financial year COLE PHARMACEUTICALS recorded a gross margin of € -168,161 and equity of € 468,254. Compared with financial year 2024, the result moved from € -592,788 to € -390,094. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What happened at COLE PHARMACEUTICALS?

What happened at COLE PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 390,094. filed late Source: NBB ↗
  • GUILLAUME DE VIRON stepped down as director. NBB
  • GUILLAUME DE VIRON became a director. NBB
  • JEAN-MARIE VANDEPLAS became a director. NBB
  • CLAUDE LUBICKI became a director. NBB
  • New establishment in Mont-Saint-Guibert. KBO
  • Start of the company according to the CBE. KBO

In short

From € 651,525 loss in 2021 to € 390,094 loss in 2025.

A new publication or filing at COLE PHARMACEUTICALS? We notify you, reason included.

Follow COLE PHARMACEUTICALS

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

JEAN-MARIE VANDEPLAS
CLAUDE LUBICKI
COLE PHARMACEUTICALS

Behind COLE PHARMACEUTICALS are JEAN-MARIE VANDEPLAS and CLAUDE LUBICKI. The same people are also behind MEDICAL MARKETING CONCEPT and BIOEXPAND.

See the full network in the app

Directors

According to the 2025 annual accounts

JEAN-MARIE VANDEPLAS

Director

Also active at: MEDICAL MARKETING CONCEPT

since 2019

CLAUDE LUBICKI

Director

Also active at: BIOEXPAND

since 2019

GUILLAUME DE VIRON

Director

Also active at: Inteliphage, AYCA Investment

since 2020 · until 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Rue André Dumont 7

1435 Mont-Saint-Guibert

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

Details

Company number
0671.904.152
VAT number
BE 0671.904.152
Registered office
Rue André Dumont 7, 1435 Mont-Saint-Guibert
Names & denominations
COLE PHARMACEUTICALS · Cole Pharma
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
28 February 2017
Peppol
Active · Active since 2 Dec 2025
Activities · NACE

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in meubelen, huishoudelijke artikelen en ijzerwaren

Frequently asked questions

What is the enterprise number of COLE PHARMACEUTICALS?
The enterprise number of COLE PHARMACEUTICALS is BE0671904152.
What is the address of COLE PHARMACEUTICALS?
The registered office of COLE PHARMACEUTICALS is located at Rue André Dumont 7, 1435 Mont-Saint-Guibert.
When was COLE PHARMACEUTICALS founded?
COLE PHARMACEUTICALS was founded on 28 February 2017.
What is the main activity of COLE PHARMACEUTICALS?
The main activity of COLE PHARMACEUTICALS is "Groothandel in farmaceutische en medische artikelen" (NACE code 46460).
Does COLE PHARMACEUTICALS have a website?
No website is currently known for COLE PHARMACEUTICALS.
How much profit did COLE PHARMACEUTICALS make in 2025?
COLE PHARMACEUTICALS recorded a loss after taxes of € 390,094 in financial year 2025.
What is the revenue of COLE PHARMACEUTICALS?
As a small company, COLE PHARMACEUTICALS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -168,161.
Where can I find the annual accounts of COLE PHARMACEUTICALS?
COLE PHARMACEUTICALS files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of COLE PHARMACEUTICALS?
According to the 2025 annual accounts, the directors of COLE PHARMACEUTICALS are: JEAN-MARIE VANDEPLAS , CLAUDE LUBICKI, GUILLAUME DE VIRON .
Who owns COLE PHARMACEUTICALS?
Behind COLE PHARMACEUTICALS are JEAN-MARIE VANDEPLAS and CLAUDE LUBICKI. The same people are also behind MEDICAL MARKETING CONCEPT and BIOEXPAND.